Blood pressure-lowering efficacy of reserpine for primary hypertension

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 12, 2016, Pages

  Shamon, Sandy D ^a   Perez, Marco I ^b  

^a Medical Clinic   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RESERPINE; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; HEART RATE; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIMARY HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; CHEMISTRY; DRUG EFFECTS; RAUWOLFIA;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEART RATE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAUWOLFIA; RESERPINE;

EID: 85006827039     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007655.pub3     Document Type: Review

References (78)

1. Kfogsgaard AR. Hypotensive effect of reserpine compared with phenobarbital and placebo. Acta Medica Scandinavica 1957;157(5):379-85. [3043569]
2. Shapiro AP, Teng HC. Technic of controlled drug assay illustrated by a comparative study of Rauwolfia serpentina, phenobarbital and placebo in the hypertensive patient. The New England Journal of Medicine 1957;256(21):970-5. [3043571]
3. Veterans Administration Cooperative Group (VACS). A double blind control study of antihypertensive agents. I. Comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamyamine, and pentolinium tartrate. Archives of Internal Medicine 1960;106:81-96. [3043573]
4. Velasco M, Arbona J, Guevara J, Torres J. A randomized double-blind study of furosemide-reserpine in essential hypertension. Current Therapeutic Research, Clinical and Experimental 1975;18(3):395-9. [3043575]
5. Achor RW, Hanson NO, Gifford RW Jr. Hypertension treated with Rauwolfia serpentina and with reserpine; controlled study disclosing occasional severe depression. Journal of the American Medical Association 1955;159(9):841-5. [3043577]
6. Bello CT, Turner LW. Reserpine as an antihypertensive in the outpatient clinic, a double blind clinical study. The American Journal of the Medical Sciences 1956;232(2):194-7. [3043579]
7. Christman RS. Efficacy of Rauwolfia serpentina preparations in the treatment of hypertension in general medical practice: a clinical comparison of three regimens. American Practitioner and Digest of Treatment 1956;7(4):614-7. [3043581]
8. Johnson RW, Sosa G, Morita Y, Mader IJ. Anti-hypertensive effects of chlorothiazide, reserpne and placebo. A double-blind evaluation. Michigan State Medical Society 1961;60:1420-3. [3043583]
9. Lee R, Seligmann AM, Goebel D, Fulton LA, Clark MA. Reserpine-hydralazine combination therapy of hypertensive disease, with hydralazine in doses generally below the toxic range. Annals of Internal Medicine 1956;44(3):456-65. [3043585]
10. Palmer RS. The hypotensive action of Rauwolfia serpentina and reserpine: a double hidden placebo study of ambulatory patients with hypertension. American Practitioner and Digest of Treatment 1955;6(9):1323-7. [3043587]
11. Sheldon MB, Kotte JH. Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study. Circulation 1957;16(2):200-6. [3043589]
12. Sosa G, Morita Y, Mader IJ. A double blind evaluation of the antihypertensive effect of reserpine, phenobarbital, hydralazine, syrosingopine, and placebo in ambulatory subjects. Angiology 1960;11(5):381-6. [3043591]
13. Suckle E. Comparison of Rauwolfia drugs in treatment of hypertension. Geriatrics 1956;11(11):509-13. [3043593]
14. Agnew TM, Irvine ROH, North JDK. Methyldopa and hydrochlorothiazide compared with reserpine and hydrochlorothiazide in hypertension. British Medical Journal 1963;2(5360):781-3.
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.
16. Blackman JG, Campion DS, Fastier FN. Mechanism of action of reserpine in producing gastric haemorrhage and erosion in the mouse. British Journal of Pharmacology and Chemotherapy 1959;14(1):112-6.
17. Bracharz H, Laas H. Clinical-pharmacologic studies and therapy with anti-hypertensive furosemide-reserpine preparations. Medizinische Klinik 1971;66(23):1113-7.
18. Chakravarty NK, Rai Chaudhuri MN. Rauwolfia serpentina in essential hypertension. Indian Medical Gazette 1951;86(8):348-54.
19. Chekman IS. Experimental investigation of the mechanism of action of reserpine. Bulletin of Experimental Biology and Medicine 1972;73(3):291-3.
20. Divitiis O, Petitto M, Di Somma S. Atenolol, chlorthalidone, and reserpine in mild-moderate hypertension: double-blind comparison. Drugs Under Experimental & Clinical Research 1981;7(6):773-9.
21. Doyle AE, Smirk FH. Hypotensive action of reserpine. Lancet 1954;266(6822):1096-7.
22. Ferguson RK, Rothenberg RJ. Comparative efficacy of reserpine and guanethidine in thiazide-treated patients with mild to moderate essential hypertension. Clinical Pharmacology & Therapeutics 1975;17(2):233.
23. Ferguson RK, Rothenberg RJ, Nies AS. Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine. Circulation 1976;54(1):32-7.
24. Finnerty FA. The value of rauwolfia serpentine in the hypertensive patient. American Journal of Medicine 1954;17(5):629-40.
25. Finnerty FA Jr, Gyftopoulos A, Berry C, McKenney A. Step 2 regimens in hypertension. An assessment. JAMA 1979;241(6):579-81.
26. Finnerty FA Jr. Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. Journal of Clinical Pharmacology 1980;20(5-6 Pt 1):357-63.
27. Gaskin R. The clinical effectiveness of dihydroergocristine - reserpine clopamide combination in the treatment of hypertension. Standing Advisory Committee for Medical Research in the British Caribbean Bahamas 1972;17th Scientific Meeting:56p.
28. Glazer N. Reserpine, hydralazine, hydrochlorothiazide combination(Ser-AP-ES) in essential hypertension. Current Therapeutic Research, Clinical and Experimental 1972;14(9):561-72.
29. Griebenow R, Pittrow DB, Weidinger G, Mueller E, Mutschler E, Welzel D. Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor. Blood Pressure 1997;6(5):299-306.
30. Heran BS, Wong MM, Heran IK, James MW. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2]
31. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2]
32. Hughes WH, Dennis E, Moyer JH. Treatment of hypertension with oral reserpine alone and in combination with hydralazine and hexamethonium. The American Journal of the Medical Sciences 1955;229(2):121-34.
33. INAGAKI Yoshiaki, et al. Therapeutic efficacy of oxprenolol in essential hypertension: a double-blind comparison with reserpine. Japanese Pharmacology and Therapeutics 1978;6(4):1097-108.
34. Joesbury HE, Phillips CA, Garrett RT, Wilkes E, Smith AJ. Mild hypertension: a clinical trial conducted in hospital general practice. British Medical Journal 1976;2(6050):1476-9.
35. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
36. Kanda Y, et al. Clinical efficacy of apllobal for essential hypertension: a multicenter double-blind controlled comparison with reserpine. The Japanese Journal of Clinical and Experimental Medicine 1977;54(11):3796-804.
37. Kennedy CC, Spiekerman RE, Elveback L. Antihypertensive properties of cryptenamine used with reserpine and methyclothiazide. Journal of Pharmaceutical Sciences 1971;60(8):1139-41.
38. Krogsgaard AR. The role of reserpine in essential hypertension when used alone or combined with hydralazine. Acta Medica Scandinavica 1958;162(6):449-63.
39. Krämer KD, Ghabussi P, Hochrein H. Antihypertensive combination-therapy with inositol nicotinate in essential hypertension. Die Medizinische Welt 1977;28(27):1198-201.
40. Krönig B, Pittrow DB, Kirch W, Welzel D, Weidinger G. Different concepts in first-line treatment of essential hypertension. Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. German Reserpine in Hypertension Study Group. Hypertension 1997;29(2):651-8.
41. Kuhns K, Djuranovic R, Gehrs C, Koppen K. Comparative clinical studies on the effect of hydrazine phthalazine and the rauwolfia alkaloid reserpine on blood pressure. Klinische Wochenschrift 1954;32(37-8):930-5.
42. Labarthe DR. Methodological variation in case-control studies of reserpine and breast cancer. Journal of Chronic Diseases 1979;32(1-2):95-104.
43. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427.
44. Leary WP, Ryes AJ, Van DBK, Maharaj B. Antihypertensive effects of clopamide administered alone in combination with pindolol or with reserpine and dihydroergocristine. Current therapeutic Research, Clinical and Experimental 1989;46(6):1224-35.
45. Liebowitz D, Carbone JV. Effect of varying doses of reserpine on gastric secretion. The New England Journal of Medicine 1957;257(5):227-8.
46. Manyemba J. A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. The Central African Journal of Medicine 1997;43(12):344-9.
47. Mattes JA, Martin D. Propranolol in the treatment of essential hypertension. Journal of the American Medical Association 1977;237(21):2303-10.
48. Nicaise J, Ghirardi P. Double-blind cross-over study of the hypotensive action of reserpine alone and associated with a diuretic (mebutizide). Bruxelles Medical 1973;53(11):683-8.
49. Ogawa K, Ban M, Ito T, Watanabe T, Kobayashi T, Yamazaki N, et al. Diltiazem for treatment of essential hypertension: a double-blind controlled study with reserpine. Clinical Therapeutics 1984;6(6):844-53.
50. Parkes WE, Agarwal AP, Hunt LB. Treatment of hypertension with quinethazone alone or in combination with reserpine. The Practitioner 1969;203(214):194-8.
51. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
52. Rösler F, Wegener H, Eulenberger D, Dahme B. The effect of an antihypertensive drug during psychological stress. A double-blind study. Arzneimittel-Forschung 1975;25(6):965-72.
53. Safar ME, Weiss YA, Corvol PL, Menard JE, London GM, Milliez PL. Anti-hypertensive adrenergic-blocking agents: effects on sodium balance, the renin-angiotensin system and haemodynamics. Clinical Science and Molecular Medicine 1975;2:93s-95s.
54. Salmela PI, Jounela AJ, Karppanen H. Double-blind comparison of dihydralazine and prazosin in hypertensive patients on the diuretic-reserpine regimen. Annals of Clinical Research 1981;13(6):433-8.
55. Schmidt A, Vetter W, Dennler HJ, Groll S, Orengo P. Combined uni- and multicenter double-blind studies in hypertensive patients. Comparison of blood pressure measurements. Schweizerische Rundschau fur Medizin Praxis 1991;80(34):849-55.
56. Seedat YK, Hoosen S, Bhigjee AI. Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients. South African Medical Journal 1984;65(23):915-7.
57. Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical and Experimental Hypertension. Part A, Theory and Practice 1989;11(5-6):973-89.
58. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24):3255-64.
59. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). American Journal of Hypertension 1995;8(12 Pt 1):1147-53.
60. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276(23):1886-92.
61. Davis BR, Vogt T, Frost PH, Burlando A, Cohen J, Wilson A, et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. Stroke 1998;29(7):1333-40.
62. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Archives of Internal Medicine 1998;158(12):1340-5.
63. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Archives of Internal Medicine 1998;158(7):741-51.
64. Patel AB, Kostis JB, Wilson AC, Shea ML, Pressel SL, Davis BR. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke 2008;39(4):1084-9.
65. Smith WM, Thurm RH, Bromer L. Comparative evaluation of Rauwolfia whole root and reserpine. Clinical Pharmacology and Therapeutics 1969;10(3):338-43.
66. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circulation Research 1977;40(5 Suppl 1):I98-205.
67. Stein CM, Neill P, Mwaluko GM, Kusema T. Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe. South African Medical Journal 1990;77(5):243-5.
68. Stuppy LJ, Tober JN. Treatment of hypertension with reserpine (serpasil) alone and in combination with hydralazine (apresoline). Angiology 1955;6(3):253-9.
69. Torsti P, Neuvonen PJ, Vapaatalo HI, Idänpään-Heikkilä JE. Circulatory and diuretic effects of hydrochlorothiazide and reserpine in man. Annals of Clinical Research 1969;1(2):126-30.
70. Veterans Administration-National Heart, Lung, and Blood Institute (VA-NHLBI) Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Annals of the New York Academy of Sciences 1978;304:267-92.
71. Veterans Administration Cooperative Study (VACS) Participants. Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone. JAMA 1982;248(19):2471-7.
72. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990;15(4):348-60.
73. Van Hoose MC, Cutler RE. Antihypertensive efficacy of metolazone (Zaroxolyn) alone and combined with reserpine in treatment of essential hypertension. Current Therapeutic Research, Clinical and Experimental 1976;20(3):266-76.
74. Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. The New England Journal of Medicine 1953;248(2):48-53.
75. Wolff FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. Journal of Chronic Diseases 1966;19(3):227-40.
76. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?. CMAJ 1999;161(1):25-32.
77. Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2008;168(2):207-17.
78. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2]